abstract |
The present invention provides a pharmaceutical composition for preventing or treating skin rash comprising epidermal growth factor as an active ingredient. The skin rash includes a skin disorder caused by administering an epidermal growth factor receptor inhibitor, such as erlotinib, as an adverse event. |